The effect of different methods of storage on the results of serum total CO2 assays

2001 ◽  
Vol 100 (6) ◽  
pp. 609-611 ◽  
Author(s):  
Matthew L. P. HOWSE ◽  
Maureen LEONARD ◽  
Michael VENNING ◽  
Laurence SOLOMAN
Keyword(s):  
Renal Failure ◽  
Metabolic Acidosis ◽  
Room Temperature ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Clinically Significant ◽  
End Stage

Metabolic acidosis frequently complicates end-stage renal failure. In haemodialysis patients its severity is usually monitored by measurement of the total CO2 (TCO2) level. Samples from ‘satellite dialysis’ patients are often stored prior to analysis. We investigated the affect of storage of 21 samples for 24 h under different conditions prior to analysis. If samples were stored at room temperature the TCO2 fell from 22.7±4.2 mmol/l to 21.6±3.7 mmol/l (P = 0.001). If the same samples were spun and stored at 4 °C the TCO2 was 22.4±3.9 mmol/l (P = not significant). We conclude that the magnitude in the fall of TCO2 stored at room temperature for 24 h is unlikely to be clinically significant and can be prevented by spinning the sample and refrigerating it.

scholarly journals Aluminum, Iron, Lead, Cadmium, Copper, Zinc, Chromium, Magnesium, Strontium, and Calcium Content in Bone of End-Stage Renal Failure Patients

1999 ◽  
Vol 45 (9) ◽  
pp. 1548-1556 ◽  
Author(s):  
Patrick C D’Haese ◽  
Marie-Madeleine Couttenye ◽  
Ludwig V Lamberts ◽  
Monique M Elseviers ◽  
William G Goodman ◽  
...  
Keyword(s):  
Renal Failure ◽  
Trace Elements ◽  
Trace Metals ◽  
Trace Metal ◽  
Renal Osteodystrophy ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Metal Contents ◽  
Bone Biopsies ◽  
End Stage

Abstract Background: Little is known about trace metal alterations in the bones of dialysis patients or whether particular types of renal osteodystrophy are associated with either increased or decreased skeletal concentrations of trace elements. Because these patients are at risk for alterations of trace elements as well as for morbidity from skeletal disorders, we measured trace elements in bone of patients with end-stage renal disease. Methods: We analyzed bone biopsies of 100 end-stage renal failure patients enrolled in a hemodialysis program. The trace metal contents of bone biopsies with histological features of either osteomalacia, adynamic bone disease, mixed lesion, normal histology, or hyperparathyroidism were compared with each other and with the trace metal contents of bone of subjects with normal renal function. Trace metals were measured by atomic absorption spectrometry. Results: The concentrations of aluminum, chromium, and cadmium were increased in bone of end-stage renal failure patients. Comparing the trace metal/calcium ratio, significantly higher values were found for the bone chromium/calcium, aluminum/calcium, zinc/calcium, magnesium/calcium, and strontium/calcium ratios. Among types of renal osteodystrophy, increased bone aluminum, lead, and strontium concentrations and strontium/calcium and aluminum/calcium ratios were found in dialysis patients with osteomalacia vs the other types of renal osteodystrophy considered as one group. Moreover, the concentrations of several trace elements in bone were significantly correlated with each other. Bone aluminum was correlated with the time on dialysis, whereas bone iron, aluminum, magnesium, and strontium tended to be associated with patient age. Bone trace metal concentrations did not depend on vitamin D intake nor on the patients’ gender. Conclusions: The concentration of several trace elements in bone of end-stage renal failure patients is disturbed, and some of the trace metals under study might share pathways of absorption, distribution, and accumulation. The clinical significance of the increased/decreased concentrations of several trace elements other than aluminum in bone of dialysis patients deserves further investigation.

COMPARISON OF OBESITY DIAGNOSTIC METHODS IN CHRONIC HEMODIALYSIS PATIENTS

2021 ◽  
Vol 2 (1) ◽  
pp. 60-65
Author(s):  
Filinjuk P.Ju.
Keyword(s):  
Renal Failure ◽  
Sensitivity And Specificity ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Diagnostic Methods ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Treat Ment ◽  
End Stage ◽  
Bioimpedance Measurement

The article deals with the problem of diagnosing obesity in patients with end-stage renal failure receiving treat-ment with programmed hemodialysis. The aim of the work was to study the indicators of the information content of various methods for diagnosing obesity among dialysis patients. The objective of the study was to compare the sensitivity and specificity of such methods for diagnosing obesity as BMI, OT / OB index, BAI, electronic caliperom-etry, bioimpedance measurement. The possibility of prac-tical application of the study is to optimize the approach to methods of diagnosing obesity in dialysis patients.

Peritoneal Dialysis Using Conventional, Lactate - Containing Solution Sterilized by Ultrafiltration

1992 ◽  
Vol 15 (11) ◽  
pp. 658-660 ◽  
Author(s):  
T.S. Ing ◽  
A.W. Yu ◽  
K.D. Thompson ◽  
A.U. Ansari ◽  
A.P. McShane ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Metabolic Acidosis ◽  
End Stage Renal Failure ◽  
End Stage

Peritoneal dialysis was performed on 7 end-stage renal failure patients using an I-lactate-containing solution sterilized by ultrafiltration through polyamide filters. The patients tolerated the procedure well while their metabolic acidosis and azotemia improved.

The Effect of Somatostatin on the Hormonal Abnormalities of End Stage Renal Disease

1981 ◽  
Vol 9 (1) ◽  
pp. 1-5
Author(s):  
Thomas G Murray ◽  
Carol Eisen ◽  
Morris Grabie ◽  
Ellen Buerklin ◽  
Barry R Walker ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Control Period ◽  
Thyroid Stimulating Hormone ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Stage Renal Disease ◽  
End Stage

Patients with end stage renal disease who are maintained on haemodialysis have elevated levels of many hormones, some of which may play a role in the pathogenesis of the complications of uraemia. The infusion of synthetic somatostatin reduces the circulating level of many of these same hormones in patients with normal renal function. If the elevated hormone levels in dialysis patients could be similarly lowered, study of the pathogenitic significance of the various hormonal abnormalities would be facilitated. With this in mind, the effect of synthetic somatostatin on the circulating level of growth hormone, glucagon, insulin, gastrin, parathyroid hormone, and thyroid stimulating hormone in dialysis patients was investigated. In pilot protocol, a dose of 2 mg of somatostatin infused over 24, 18, or 12 hours (two patients each) was found to have no effect on any hormonal level. Infusion of 2 mg of somatostatin over 4 hours, however, was associated with consistent fall in the level of growth hormone (13.6 ± 6.2 to 6.53 ± 2.9, p = 0.15) and glucagon (595.0 ± 73 to 441 ± 28, p < 0.05) in each of four patients. The percentage change in the level of growth hormone and glucagon during the 4-hour somatostatin infusion was significantly different from the change occurring during a 4-hour timed control period (growth hormone —45 ± 18% vs +9 ± 7%, [p < 0.05]), (glucagon −27% ± 2% vs + 8 ± 2%, [p < 0.01]). There was no change in the level of any other hormone during the 4-hour infusion. No significant adverse effects were seen. This study suggests that the intravenous infusion of somatostatin can, at least on an acute basis, lower the level of growth hormone and glucagon in patients with end stage renal failure; and, therefore, it may be useful in further study and possibly the treatment of the hormonal abnormalities of end stage renal disease.

scholarly journals Polymorphism of the ACE Gene in Dialysis Patients: Overexpression of DD Genotype in Type 2 Diabetic End-Stage Renal Failure Patients

2005 ◽  
Vol 46 (6) ◽  
pp. 779 ◽  
Author(s):  
Hyeong Cheon Park ◽  
So Rae Choi ◽  
Beom Seok Kim ◽  
Tae Hee Lee ◽  
Byung Seung Kang ◽  
...  
Keyword(s):  
Renal Failure ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Ace Gene ◽  
End Stage ◽  
Type 2 Diabetic

DYSPEPSIA SYNDROME AND HELICOBACTER PYLORI INFECTION IN END STAGE RENAL FAILURE

2000 ◽  
Vol 15 (12) ◽  
pp. H2-H2
Author(s):  
IS Mertasudira ◽  
JR Saketi ◽  
A. Djumhana ◽  
J. Widjojo ◽  
SA Abdurachman
Keyword(s):  
Renal Failure ◽  
Helicobacter Pylori ◽  
Helicobacter Pylori Infection ◽  
End Stage Renal Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document